[Form 4] Addus HomeCare Corp Insider Trading Activity
Heather Brianne Dixon, a named officer of Addus HomeCare Corp (ADUS), reported an acquisition on 09/15/2025 of 28,370 shares of the issuer's common stock at a reported price of $0. Following the reported transaction, Ms. Dixon beneficially owns 32,189 shares, held directly. The filing includes an explanatory note that the newly reported shares vest in equal installments on September 15, 2026, September 15, 2027, and September 15, 2028, subject to customary continued-service provisions and acceleration on a change in control. The Form 4 was signed by an attorney-in-fact on 09/16/2025.
- Acquisition of 28,370 shares reported (transaction code A), increasing direct beneficial ownership to 32,189 shares
- Vesting schedule disclosed: shares vest in equal installments on Sep 15, 2026, Sep 15, 2027, and Sep 15, 2028
- Change-in-control acceleration is disclosed, clarifying terms of the equity award
- None.
Insights
TL;DR: Officer reported a sizeable grant/vesting of 28,370 shares that increases direct ownership to 32,189 shares.
The Form 4 discloses a non-cash acquisition (transaction code A) of 28,370 common shares at a reported price of $0, consistent with an equity award or grant rather than an open-market purchase. The shares are subject to time-based vesting over three annual installments and include acceleration on a change in control, which is typical for retention and alignment purposes. For investors, this is a routine executive equity grant disclosure; it changes the officer's direct stake but contains no cash proceeds or debt impact for the company.
TL;DR: Filing documents a standard restricted-equity grant with multi-year vesting and change-in-control acceleration.
The explanatory note confirms the award vests in equal installments over three years and includes customary acceleration on a change in control. The structure indicates retention incentives and potential alignment of management with shareholder outcomes without immediate dilutionary cash impact. The report is filed by a single reporting person and signed by an attorney-in-fact, satisfying procedural reporting requirements. No unusual terms or immediate insider sales are disclosed.